Celsion Corporation (CLSN)

[macnqueso]

That seems an odd choice as a comparison...

Ridaforolimus, Ariad/Merck's sarcoma drug actually met its PFS endpoint, albeit modestly... it was rejected by AdCom 13-1 in March of last year and then officially rejected by the FDA in June... Here is an excerpt...

"In a late stage SUCEED study by Ariad Pharmaceuticals and Merck, patients with soft tissue sarcoma who took ridaforolimus showed a median progression free survival rate of 17.7 weeks, higher by three weeks compared to those on placebo.

However, an FDA analysis contended that the difference in survival rate was about two weeks, and also raised concerns over the drug's effects like infections and kidney damage."

Between ridaformolimus and thermodox there is little comparison regarding mechanism of action, safety profile, etc... I don't think much of this comparison... am I missing something?

http://www.rttnews.com/1844915/fda-panel-rejects-ariad-merck-s-sarcoma-drug-ridaforolimus.aspx